A phase II randomized trial of evaluation for bortezomib in refractory Systemic lupus erythematosus: cross over additional trial
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 12 Dec 2015 Status changed from recruiting to completed, according to the University Hospital Medical Information Network - Japan record.
- 03 Jul 2014 According to the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.
- 17 Apr 2014 New trial record